

Periorbital/Preseptal Cellulitis in Adults - Microbiology Summary Clinical Guideline

Reference number: CG-ANTI/2017/079

Symptoms and signs of periorbital/preseptal cellulitis (eyelid redness, tenderness, and swelling; with or without ocular pain)

Differential diagnosis

- The symptoms and signs of periorbital/preseptal cellulitis may overlap with the eyesight- and life-threatening orbital/postseptal cellulitis
- Ocular pain (especially on eye movements), ophthalmoplegia, proptosis, visual disturbance (for example: reduced visual acuity; diplopia), and/or visual loss can be distinguishing features of orbital/postseptal cellulitis

Investigation

- ± CT orbits and sinuses (for example, if differential diagnosis includes orbital/postseptal cellulitis); ± bloods (FBC, CRP, lactate, U&Es, and LFTs), ± blood cultures

Treatment

- Criteria for intravenous: (1) septic shock; (2) sepsis; (3) progression of symptoms and signs after 48 hours of per oral antibiotics; (4) intolerant of per oral antibiotics

Criteria (1): intravenous therapy in ICU

- First line: co-amoxiclav 1.2 g 8 hourly
- Second line: glycopeptide (vancomycin or teicoplanin), [dose as per hospital guidelines](#), and metronidazole 500 mg 8 hourly
- Third line: clindamycin 600 mg 6 hourly

Criteria (2): intravenous therapy in hospital ± ICU

- First line: co-amoxiclav 1.2 g 8 hourly
- Second line: glycopeptide (vancomycin or teicoplanin), [dose as per hospital guidelines](#), and metronidazole 500 mg 8 hourly
- Third line: clindamycin 600 mg 6 hourly

Criteria (3) or (4): intravenous therapy in hospital or via OPAT

- Hospital:
 - First line: co-amoxiclav 1.2 g 8 hourly
 - Second line: glycopeptide (vancomycin or teicoplanin), [dose as per hospital guidelines](#), and metronidazole 500 mg 8 hourly
 - Third line: clindamycin 600 mg 6 hourly
- OPAT:
 - First line: ceftriaxone 2-4 g daily and metronidazole 400 mg (per oral) 8 hourly
 - Second line: teicoplanin and metronidazole 400 mg (per oral) 8 hourly
 - Third line: daptomycin 4-6 mg/kg daily and metronidazole 400 mg (per oral) 8 hourly

No criteria for intravenous: per oral antibiotics in the community

- First line: co-amoxiclav 625 mg 8 hourly.
- Second line: clindamycin 300-450 mg 6 hourly.
- Third line: clarithromycin 500 mg 12 hourly and metronidazole 400 mg 8 hourly

References

Bennett, J. E., Dolin, R., and Blaser, M. J. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition. Elsevier.

BMJ. 2020. Peri-orbital and orbital cellulitis. Available at: <https://bestpractice.bmj.com/topics/en-gb/734> (accessed February 2021).

Gappy, C., Archer, S. M., and Barza, M. 2020. Preseptal cellulitis. Available at: <https://www.uptodate.com/contents/preseptal-cellulitis> (accessed July 2020).

Document Control

Development of guidelines:	Dr Chris Durojaiye, Angelina Dyche, Dr Ravi Kothari, Dr Julia Lacey, Dr Carlene Rowson, Dr Peter Slovak
Consultation with:	Antimicrobial Pharmacists, Infectious Diseases and OPAT Consultants, Microbiology Consultant, Radiology Consultant
Version:	1.1.0
Approval date:	Antimicrobial Stewardship Committee - 05/08/2021 Surgical Division – 17/08/2021
Changes from previous version:	N/A
Date uploaded:	22/09/2021
Next review date:	August 2024
Key contacts:	Dr Peter Slovak, Microbiology Consultant p.slovak@nhs.net Kayleigh Lehal, Antimicrobial Pharmacist kayleigh.lehal@nhs.net